Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Vitamin E, including its beta and delta tocopherol forms, has been investigated for its potential role in supporting or treating Inflammatory Bowel Disorders (IBD) such as Crohn’s disease and ulcerative colitis. The rationale for its use is primarily based on its antioxidant properties, as oxidative stress and inflammation are central features in the pathophysiology of IBD. Preclinical studies in animal models have shown that Vitamin E supplementation can reduce markers of oxidative damage and inflammation in colonic tissues. Furthermore, some in vitro studies suggest that tocopherols may modulate inflammatory signaling pathways and cytokine production relevant to IBD.

However, evidence from human clinical trials is limited and inconsistent. While a few small studies have found improvements in oxidative stress markers and some symptomatic relief in IBD patients taking Vitamin E, these studies often use alpha-tocopherol rather than the beta or delta forms, and sample sizes are typically small. Larger, well-controlled human trials are lacking, and there is not yet consensus regarding dosing, efficacy, or the preferred tocopherol isoform. Current clinical guidelines do not endorse Vitamin E as a primary or adjunctive therapy for IBD.

In summary, the use of Vitamin E (including beta and delta tocopherols) in IBD is scientifically motivated due to its antioxidant and anti-inflammatory properties, but the strength of evidence in human populations is low (rated 2/5), and further research is necessary to establish its role in clinical practice.

More about Vitamin E (beta and delta tocopherols)
More about Inflammatory Bowel Disorders

Other ingredients used for Inflammatory Bowel Disorders

Other health conditions supported by Vitamin E (beta and delta tocopherols)

Products containing Vitamin E (beta and delta tocopherols)